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A Randomized, Open-label, Phase 3, Superiority Study 
Of Pemetrexed (Pem)+Carboplatin (Cb)+Bevacizumab 
(B) Followed By Maintenance Pem+B Versus Paclitaxel 
(Pac)+Cb+B Followed By Maintenance B In Patients (pts) 
With Stage IIIB Or IV Non-squamous Non-small Cell Lung 
Cancer (NS-NSCLC)
J. Patel1, M. A. Socinski2, E. B. Garon3, C. H. Reynolds4, D. R. Spigel5, R. 
C. Hermann6, J. Liu7, S. C. Guba7, P. Bonomi8, R. Govindan9, 1Northwestern 
University, Chicago, IL, 2University of Pittsburgh Medical Center Cancer 
Pavilion, Pittsburgh, PA, 3University of California Los Angeles/Translational 
Oncology Research International, Los Angeles, CA, 4Ocala Oncology and 
US Oncology Research, Inc., Ocala, HI, 5SCRI/Tennessee Oncology, PLLC, 
Nashville, TN, 6Northwest Georgia Oncology Centers, Marietta, GA, 7Eli Lilly 
and Company, Indianapolis, IN, 8Rush University Medical Center, Chicago, 
IL, 9Washington University School of Medicine, St. Louis, MO
Purpose/Objective(s): Both Pac+Cb+B and Pem+cisplatin are approved for 
first-line treatment of advanced NS-NSCLC. In a Ph 2 study, Pem+Cb+B 
showed promising overall survival (OS) and progression-free survival (PFS). 
The objective of this Ph 3 study was to compare Pem+Cb+B followed by 
Pem+B (Pem Arm) with Pac+Cb+B followed by B (Pac Arm) in pts with 
advanced NS-NSCLC. 
Materials/Methods: Pts with previously untreated stage IIIB/IV NS-NSCLC 
and ECOG performance status (PS) of 0-1 were randomized to receive 
Pem+Cb+B (Pem 500 mg/m2; Cb AUC 6; B 15 mg/kg) and folic acid, vitamin 
B
12
 and dexamethasone supplementation or Pac+Cb+B (Pac 200 mg/m2; Cb 
AUC 6; B 15 mg/kg), and dexamethasone, diphenhydramine, and cimetidine 
or ranitidine premedications, every 3 weeks for up to 4 cycles. Pts continuing 
without progressive disease received maintenance Pem+B (Pem Arm) or B 
(Pac Arm). The primary endpoint of this superiority study was OS; second-
ary endpoints included PFS, objective response rate (ORR), disease control 
rate (DCR) and toxicity. The study assumed a hazard ratio (HR) of 0.80 and 
required 676 events in 900 pts to yield at least an 80% power to demonstrate 
superiority of Pem Arm over Pac Arm using a log-rank test with 1-sided type I 
error of 0.025. Efficacy analyses included all randomized pts; safety analyses 
included pts who received at least 1 dose of a study drug. 
Results: 939 pts were randomized to Pem+Cb+B (n=472) or Pac+Cb+B 
(n=467). Prognostic factors and characteristics were well balanced between 
arms: median age 64.7 years, 53.2% male, 55.9% PS 1, 90.0% stage IV 
NSCLC, 85.7% Caucasian, 79.2% adenocarcinoma and 11.6% never smok-
ers. For Pem Arm vs Pac Arm, median OS was 12.6 vs 13.4 mo (HR 1.00, 
p=0.949); median PFS, 6.0 vs 5.6 mo (HR 0.83, p=0.012); ORR, 34.1% vs. 
33.0%; and DCR, 65.9% vs 69.8%. Significantly more study drug-related 
grade 3/4 anemia (14.5% vs 2.7%), thrombocytopenia (23.3% vs 5.6%) and 
fatigue (10.9% vs 5.0%) were seen on Pem Arm; significantly more grade 
3/4 neutropenia (40.6% vs 25.8%), febrile neutropenia (4.1% vs 1.4%), sen-
sory neuropathy (4.1% vs 0) and complete alopecia (grade 2) (21.4 % vs 
1.1%) were seen on Pac Arm. Study drug-related discontinuations due to SAE 
(2.7% vs 3.6%), AE (10.4% vs. 9.0%) and study drug-related deaths due to 
AE (1.8% vs 2.3%) were similar (Pem vs Pac, respectively). Exploratory KM 
analyses for pts treated with maintenance therapy were 17.7 vs 15.7 mo for 
OS and 8.6 vs 6.9 mo for PFS (Pem n=292 vs. Pac n=298 respectively). 
Conclusions: The primary endpoint of superior OS was not met in this trial, 
although Pem+Cb+B improved PFS. Toxicity profiles differed and both regi-
mens demonstrated tolerability.
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Bavituximab (B), a monoclonal antibody directed against phosphatidylserine, 
(PS) has been shown to localize selectively to tumor vasculature, synergize 
with chemotherapy, cause vascular shutdown in tumors and reactivate innate 
and adaptive tumor immunity. 
Purpose/Objective(s): To evaluate the efficacy and safety of two separate 
doses of bavituximab (1 and 3 mg/kg) combined with docetaxel (D) vs. D 
plus placebo (P) as second line therapy in patients with locally advanced or 
metastatic non-squamous NSCLC. 
Materials/Methods: This phase II, multicenter, double-blind study, random-
ized patients (1:1:1) to receive 75 mg/m2 of D every 21 days up to 6 cycles and 
weekly blinded infusion of P, 1 mg/kg or 3 mg/kg of B until disease progres-
sion or toxicity. Key eligibility criteria were Stage IIIB and IV, non-squamous 
NSCLC previously treated with first line systemic chemotherapy, ECOG sta-
tus ≤2, measurable disease by RECIST and adequate hematologic, hepatic 
and renal function. The primary efficacy endpoint was overall response rate 
(ORR) by RECIST 1.1 and secondary endpoints were progression free sur-
vival (PFS), duration of response (DR) and overall survival (OS). Safety was 
evaluated by adverse events, vital signs, laboratory measurements (CBC, bio-
chemistry, urinalysis and coagulation), ECG and human anti-chimeric anti-
body (HACA) formation. 
Results: Of the 121 patients randomized, no significant differences were seen 
in baseline characteristics (gender, age, ethnicity, ECOG or disease stage.) 
Based on 117 evaluable patients, the ORR was 7.9% for the D + P, 15.0% 
for the D + 1 mg/kg B and 17.9 % for the D + 3 mg/kg B cohorts, respec-
tively. Median PFS was 3.0, 4.2 and 4.5 months, respectively. At the time the 
Independent Data Monitoring Committee (IDMC) recommended to unblind 
the trial, median OS had been reached at 5.4 months in the control group 
(61% death events), while <35% of death events had been observed in the 
bavituximab-containing groups. B + D was well-tolerated and no safety con-
cerns were identified by the IDMC. 
Conclusions: In this double-blind, randomized, placebo-controlled, mul-
ticenter Phase II study in patients with Stage IIIB and IV non-squamous 
NSCLC, bavituximab in combination with docetaxel was well-tolerated and 
all endpoints (response, PFS and OS) demonstrated trends toward superior-
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been reached in either bavituximab-containing cohort, there is a clear and 
persistent separation of the survival curves warranting further development 
of bavituximab.
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Purpose/Objective(s): The study enrolled 107 patients (pts) with stage IIIB/
IV NSCLC who progressed following at least one line of therapy or refused 
standard chemotherapy. Pts were randomized to erlotinib (150mg/day)/high 
dose celecoxib (E/HD-C) (600mg/2x day) vs. erlotinib/placebo (E/P), strati-
fied by smoking status and ECOG performance status. The primary endpoint 
was progression-free survival (PFS); secondary endpoints included response 
rate, overall survival (OS) and evaluation of molecular markers in tissue and 
serum. VeriStrat (VS) is a clinically validated pretreatment serum proteomic 
analysis for advanced NSCLC pts that identifies patients with better or worse 
outcomes on E. 
Materials/Methods: Retrospective analysis of serum samples was performed 
with the VS test; 98 baseline pre-treatment samples were available for the 
analysis, 96 samples were run (2 excluded due to hemolysis). PFS was calcu-
lated from randomization to progression or death or to the date of last contact 
in the absence of progression. OS was calculated from randomization to death 
or last contact. Survival analysis was carried out using SAS Enterprise Guide 
(SAS 9.2) and Prism (GraphPad 5). Difference between groups was assessed 
using log-rank p values estimated by Mantel-Cox method and p-values 
obtained from Cox proportional hazards model (CPH). Both univariate and 
multivariate hazard ratios were evaluated using CPH models. Kaplan-Meier 
plots and p values for contingency tables were generated using PRISM. 
Results: Of 96 samples that received VS classification, 69 were classified as 
Good, 26 as Poor, and 1 indeterminate. There was a significant correlation 
between VS classification and DCR in combined arms (p = 0.0096) and in 
E/HD-C arm (p = 0.0080); ORR was also significantly correlated with VS in 
combined arms (p = 0.002). There was no significant correlation between VS 
classification and mutation status. VS Good classification was significantly 
associated with longer PFS (p < 0.0001) and OS (p < 0.0001) in E/HD-C 
treatment arm and with longer OS in E/P arm (p = 0.001). Analysis of VS 
Good stratified by EGFR mutation status showed benefit in PFS from the 
addition of HD-C may be associated with EGFR wild type, but probably not 
with EGFR mutation. Multivariate analysis yielded VS classification, smok-
ing status and EGFR mutation as significant for PFS; only VS remained sig-
nificant for OS. 
Conclusions: The observed significant interaction between treatment arms 
and VS classification and PFS indicates the predictive properties of VS in 
this population treated with E/HD-C or E/P. Results suggest that pts with VS 
Good classification and EGFR wild type might benefit more from the addi-
tion of HD-C to E than from E alone. If validated, VS may be used to identify 
NSCLC patients benefiting from the addition of HD-C to E to their treatment 
regimen.
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Purpose/Objective(s): The goal of the study was to determine the ability of 
small lung biopsies performed by bronchoscopy or CT guidance to correctly 
identify the histologic subtype of primary non small cell lung cancer and 
examine factors that would affect accuracy. 
Material/Methods: A retrospective review of 281 patients who had a lobec-
tomy at the University of Arkansas for Medical Sciences between 2002 and 
2011 was performed to determine which patients had a biopsy prior to sur-
gery by either bronchoscopy or CT guidance. One hundred seventeen patients 
(51 females and 66 males, median age 64 years) had a total of 119 biopsies 
(39 bronchoscopy, 72 CT guided, 8 unknown procedures) prior to having 
lobectomy. The histologic diagnosis (squamous, non-squamous, and adeno-
squamous) of the biopsy was compared to the histologic diagnosis from the 
lobectomy specimen, and the correlation rate was determined. Subgroup anal-
yses were performed based on tumor location (central vs peripheral lesions), 
type of biopsy procedure, pre-operative stage and post-operative stage were 
performed. 
Results: The pre-operative biopsy correctly identified the histologic diagno-
sis in 81 of 119 specimens for an overall concordance rate was 68.1%. The 
concordance rate prior to the 2007 American Society of Clinical Oncology 
national meeting, when the data for pemetrexed in advanced non small cell 
lung cancer were first presented was 70.2% (33 of 47 specimens correct). 
The concordance rate after American Society of Clinical Oncology 2007 
was 66.7% (48 of 72 specimens correct). The concordance rate after July 
2008, when the data for pemetrexed were published in the Journal of Clinical 
Oncology was 75% (42 of 56 specimens correct). Comparisons of the con-
cordance rates based on these dates were not statistically significant with two 
sided p = 0.8408 for pre vs post ASCO 2007 and two sided p = 0.1680 for pre 
vs post Journal of Clinical Oncology July 2008. Subgroup analyses did not 
show a statistically significant difference in concordance rate based on tumor 
location (p = 0.6301), type of biopsy procedure (p = 0.7726), pre-operative 
stage (p = 0.9952), and post-operative stage (p = 0.4429). 
Conclusion: The concordance rate for histologic diagnosis between pre- 
operative biopsy and lobectomy is 68.1%. No factors have yet been identified 
to predict which patients are at higher risk for an inaccurate histologic diagno-
sis. This information will be important for care of patients with advanced non 
small cell lung cancer since treatment is often guided by histology.
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and as Maintenance Therapy in Extensive-Stage Small Cell 
Lung Cancer (SCLC)- Final Results
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Purpose/Objective(s): Sorafenib (S) is a small molecule multi-tyrosine 
kinase inhibitor of Raf kinase, VEGFR, and PDGFR. Angiogenesis is impor-
tant for growth and progression of SCLC. This trial was conducted to evaluate 
whether the combination of cisplatin (P) and etoposide (E) plus concurrent and 
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sequential S could prolong survival at one year in patients (pts) with previously 
untreated SCLC. 
Materials/Methods: Previously untreated pts with extensive stage SCLC, 
with ECOG 0-2 and adequate organ function were treated with P 60 mg/m2 
day 1, E 120 mg/m2 days 1, 2, 3 x 4 cycles, concurrent with S 200mg orally 
bid starting day 1 cycle 1. Pts with no disease progression after 4 cycles con-
tinued S 400mg orally bid as maintenance for maximum of 12 months or until 
unacceptable toxicity, disease progression or withdrawal from the study. The 
primary endpoint was one year survival with response rate and safety of the 
combination as secondary endpoints. Total accrual of 28 pts from 3 centers 
was planned. Response and progression were monitored by CT’s every 8 week 
using RECIST criteria. 
Results: A total of 18 patients were enrolled into the trial from 3 sites between 
August 2008 and November 2011. 12 and 17 pts were evaluable for response 
and adverse effects (AEs) respectively. Median age was 63 years (range 45 to 
82), 9 pts (53%) were male. One pt had CR, 7 pts had PR and 1 pt had stable 
disease with an overall response rate of 67%. Overall median survival was 
7.4 months and 1 year survival among response evaluable pts was 25%. The 
most common treatment-related adverse events included fatigue, anorexia, 
rash, diarrhea, neutropenia and weight loss. Grade 5 GI bleeding, pulmonary 
hemorrhage and neutropenia occurred in one pt (5%) each. Grade 4 events 
included neutropenia: 8 pts (47%), pneumonitis, thrombocytopenia and hypo-
calcemia in one pt each. Grade 3 events included supraventricular tachycar-
dia: 2 pts (11%), hypocalcaemia and hyponatremia in two pts each. Accrual 
was halted on the basis of safety profile as well as preliminary efficacy data. 
Conclusions: Although the combination of EP plus S has anti-tumor activ-
ity in patients with extensive stage SCLC, at the current dose levels, this 
combination has significant AEs, is unlikely to be superior to standard treat-
ment and is not recommended for further study (supported by a grant from 
Bayer-Onyx).
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